Trial Profile

A real world study assessing XARELTO® (rivaroxaban) in newly dignosed patients with nonvalvular atrial fibrillation (NVAF)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Warfarin
Indications Atrial fibrillation
Focus Therapeutic Use
Sponsors Janssen Pharmaceuticals

Most Recent Events

26 Mar 2019 New trial record
18 Mar 2019 According to a Janssen Pharmaceuticals media Release, data from this study was presented in the American College of Cardiology's 68th Annual Scientific Session (ACC.19).
18 Mar 2019 Results published in the Janssen Pharmaceuticals media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com